---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-010973"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2025-09-22T23:59:59+00:00"
generated_at: "2026-05-17T06:03:48.916579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Palatin earns €5.5M milestone payment from Boehringer Ingelheim in retinal disease collaboration

## Summary
- Achieved research milestone in collaboration with Boehringer Ingelheim, triggering €5.5M ($6.5M) payment to Palatin.
- Collaboration, announced Aug 18, 2025, targets first-in-class melanocortin receptor treatment for diabetic retinopathy and diabetic macular edema.
- Palatin eligible for up to €278M ($328M) in success-based milestones plus tiered royalties on net sales from the collaboration.
- Upfront payment of €2M already received; total near-term research milestones of €18M including the €5.5M achieved.

## SEC filing metadata
- accession: 0001654954-25-010973
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2025-09-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495425010973/0001654954-25-010973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495425010973/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-010973
- JSON: https://secwatch.observer/filing/0001654954-25-010973.json
- Plain text: https://secwatch.observer/filing/0001654954-25-010973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.